Related Experiment Video
Updated: Jul 22, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
Ocular complications of antineoplastic therapies
Abbas Bader1, Madeline Begemann2, Ammar Al-Obaidi2
1University of Missouri Kansas City School of Medicine, 5000 Holmes St, Kansas City, MO 64110, USA.
Abstract:
Ocular complications of antineoplastic agents can have a profound effect on the quality of life of cancer patients. New oncologic treatments like monoclonal antibodies, immunotherapies, antibody-drug conjugates, checkpoint inhibitors and growth factor receptors have resulted in increased ocular complications. These ocular complications differs in respect to distinct mechanisms of actions and lead to significant challenges in the management of cancer patients. In this review, we reviewed literature, clinical studies and cases detailing ocular complications due to administration of antineoplastic agents and emphasized the need for communication between oncologists and ophthalmologists toward early detection and management of ocular complications.
Insights
New cancer treatments are increasing ocular complications, affecting patient quality of life. Early detection and management through oncologist-ophthalmologist communication are crucial for addressing these vision issues.
Area of Science:
- Oncology
- Ophthalmology
- Pharmacology
Background:
- Antineoplastic agents, including novel therapies, can cause significant ocular complications.
- These side effects profoundly impact cancer patients' quality of life.
- Ocular toxicities vary based on the specific antineoplastic agent's mechanism of action.
Purpose of the Study:
- To review and synthesize current literature on ocular complications associated with antineoplastic agents.
- To highlight the challenges in managing these vision-related side effects in cancer care.
- To emphasize the importance of interdisciplinary collaboration for optimal patient outcomes.
Main Methods:
- Comprehensive literature review of scientific journals.
- Analysis of clinical studies and case reports.
- Synthesis of data on ocular side effects from various antineoplastic therapies.
Main Results:
- Novel cancer treatments like monoclonal antibodies, immunotherapies, and antibody-drug conjugates are associated with increased ocular complications.
- The specific type and severity of ocular toxicity depend on the antineoplastic agent's mechanism.
- Management of these complications presents significant challenges for cancer patient care.
Conclusions:
- Ocular complications are a growing concern with modern antineoplastic therapies.
- Effective management requires a thorough understanding of drug-specific toxicities.
- Enhanced communication and collaboration between oncologists and ophthalmologists are essential for early detection and timely intervention.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Accessory Structures of the Eye
Photoreceptors and Visual Pathways

